HRTX Heron Therapeutics Inc

Price (delayed)

$3.175

Market cap

$325.37M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.29

Enterprise value

$427.47M

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. Heron ...

Highlights
HRTX's revenue is up by 8% year-on-year and by 4% since the previous quarter
HRTX's gross profit is down by 14% year-on-year but it is up by 3.2% since the previous quarter
Heron Therapeutics's EPS has increased by 9% YoY but it has decreased by 2.2% QoQ
The equity has dropped by 88% year-on-year and by 69% since the previous quarter
The quick ratio has contracted by 39% from the previous quarter and by 19% YoY

Key stats

What are the main financial stats of HRTX
Market
Shares outstanding
102.48M
Market cap
$325.37M
Enterprise value
$427.47M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
13.54
Price to sales (P/S)
3.61
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.76
Earnings
Revenue
$89.79M
EBIT
-$229.98M
EBITDA
-$226.98M
Free cash flow
-$208.55M
Per share
EPS
-$2.29
Free cash flow per share
-$2.04
Book value per share
$0.23
Revenue per share
$0.88
TBVPS
$2.68
Balance sheet
Total assets
$273.72M
Total liabilities
$249.77M
Debt
$159.01M
Equity
$23.96M
Working capital
$129.59M
Liquidity
Debt to equity
6.64
Current ratio
2.39
Quick ratio
1.65
Net debt/EBITDA
-0.45
Margins
EBITDA margin
-252.8%
Gross margin
46.4%
Net margin
-258.3%
Operating margin
-254.6%
Efficiency
Return on assets
-69.4%
Return on equity
-243.9%
Return on invested capital
-78.8%
Return on capital employed
-127.3%
Return on sales
-256.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HRTX stock price

How has the Heron Therapeutics stock price performed over time
Intraday
3.42%
1 week
3.42%
1 month
-5.51%
1 year
-79.66%
YTD
-65.22%
QTD
-44.49%

Financial performance

How have Heron Therapeutics's revenue and profit performed over time
Revenue
$89.79M
Gross profit
$41.62M
Operating income
-$228.64M
Net income
-$231.96M
Gross margin
46.4%
Net margin
-258.3%
The gross margin has contracted by 20% YoY
HRTX's gross profit is down by 14% year-on-year but it is up by 3.2% since the previous quarter
HRTX's revenue is up by 8% year-on-year and by 4% since the previous quarter
HRTX's operating margin is up by 7% year-on-year

Growth

What is Heron Therapeutics's growth rate over time

Valuation

What is Heron Therapeutics stock price valuation
P/E
N/A
P/B
13.54
P/S
3.61
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.76
Heron Therapeutics's EPS has increased by 9% YoY but it has decreased by 2.2% QoQ
The equity has dropped by 88% year-on-year and by 69% since the previous quarter
The P/B is 44% higher than the 5-year quarterly average of 9.1 but 6% lower than the last 4 quarters average of 13.9
HRTX's price to sales (P/S) is 85% less than its 5-year quarterly average of 23.7 and 71% less than its last 4 quarters average of 12.0
HRTX's revenue is up by 8% year-on-year and by 4% since the previous quarter

Efficiency

How efficient is Heron Therapeutics business performance
Heron Therapeutics's ROE has plunged by 176% YoY and by 53% from the previous quarter
The ROIC has grown by 27% YoY and by 4.6% from the previous quarter
HRTX's ROA is down by 13% YoY and by 8% QoQ
Heron Therapeutics's return on sales has increased by 7% YoY

Dividends

What is HRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HRTX.

Financial health

How did Heron Therapeutics financials performed over time
Heron Therapeutics's total assets is 10% higher than its total liabilities
HRTX's total liabilities has surged by 118% year-on-year and by 9% since the previous quarter
The quick ratio has contracted by 39% from the previous quarter and by 19% YoY
The equity has dropped by 88% year-on-year and by 69% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.